The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use
Open accessAbstract
This review describes the recent Food and Drug Administration (FDA)-approved drugs (in the year 2021) containing at least one halogen atom (covalently bound). The structures proposed throughout this work are grouped according to their therapeutical use. Their synthesis is presented as well. The number of halogenated molecules that are reaching the market is regularly preserved, and 14 of the 50 molecules approved by the FDA in the last year contain halogens. This underlines the emergent role of halogens and, in particular, of fluorine and chlorine in the preparation of drugs for the treatment of several diseases such as viral infections, several types of cancer, cardiovascular disease, multiple sclerosis, migraine and inflammatory diseases such as vasculitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944 · cited 1×
“Opposite to this trend, fluorine is prevalently employed in modern medicinal chemistry [7]: eight approved drugs out of 14 in 2021 were fluorine-containing drugs, four contained chlorine and two contained a combination of the two halogens.”
BackgroundDiscovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765 · cited 1×
“In a recent publication, the authors stated that the introduction of two aromatic fluorine led to an increase in Madin−Darby canine kidney (MDCK) cell trans well permeability assay [29].”
BackgroundHalogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228 · cited 4×
“One drug (ponesimod, Ponvory®), a selective sphingosine-1-phosphate receptor 1 (S1P1)[66], was approved for relapsing multiple sclerosis (RMS) [1].”
BackgroundInfluentialXu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00719 · Cited by 220
Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182
Kang, C. (2021) · Drugs · doi:10.1007/s40265-021-01567-1 · Cited by 101 · cited 2×
“Infigratinib Infigrati ib (50, brand name Truseltiq®) is a fibroblast growth factor receptor (FGFR)specific tyrosine kinase inhibitor being codeveloped by QED Therapeutics and Helsinn for the tre tment of cholangiocarcinom , urotheli l carcinoma and oth r FGFR-driven conditions [40].”
Method
Cited by
Sweeney, D., Bogdanov, A., Chase, A. B., Castro-Falcón, G., Trinidad-Javier, A., Dahesh, S., Nizet, V., & Jensen, P. R. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00934 · Cited by 16
Balansa, W. (2023) · Jurnal Ilmiah PLATAX · doi:10.35800/jip.v11i2.48061 · Cited by 7
Metadata
- Authors
- Benedetto Tiz, D., Bagnoli, L., Rosati, O., Marini, F., Sancineto, L., & Santi, C.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-02
- Volume
- 27
- Issue
- 5
- Pages
- 1643
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W4214873930
- Cited by
- 159
- References
- 7
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use. https://app.cochat.ai/papers/10.3390/molecules27051643
- The paper
- Benedetto Tiz, D., Bagnoli, L., Rosati, O., Marini, F., Sancineto, L., & Santi, C. (2022). New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use. Molecules. https://doi.org/10.3390/molecules27051643
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.